• Dibutyryl-cAMP, Sodium Salt: Optimizing cAMP Pathway Researc

  2026-05-24

  Dibutyryl-cAMP, sodium salt (DBcAMP sodium salt) provides a powerful, stable, and cell-permeable solution for dissecting cAMP-mediated signaling in both routine and advanced experimental workflows. This article offers hands-on guidance, protocol enhancements, and troubleshooting insights to maximize reproducibility and data quality in applications from neuronal reprogramming to inflammation and tauopathy studies.

• Obacunone Induces Ferroptosis in Ovarian Cancer via Akt/p53

  2026-05-23

  This study demonstrates that Obacunone, a citrus-derived compound, induces ferroptosis and suppresses ovarian cancer cell proliferation by modulating the Akt/p53 signaling pathway. The findings provide mechanistic insight into ferroptosis regulation in cancer and highlight the potential for targeting Akt signaling in future therapeutic strategies.

• SB203580: Precision p38 MAPK Inhibition for Advanced Assays

  2026-05-22

  Unlock the full power of SB203580 in dissecting p38 MAPK signaling, enabling robust workflows in neuroprotection, multidrug resistance, and inflammation research. This guide translates recent reference breakthroughs into hands-on tips, experimental enhancements, and troubleshooting advice for reproducible, high-impact results.

• Hesperadin: Precision Aurora B Kinase Inhibitor in Mitosis R

  2026-05-22

  Hesperadin enables high-resolution dissection of mitotic checkpoints and spindle assembly, making it indispensable for cancer and cell cycle research. Its robust, ATP-competitive inhibition of Aurora B kinase delivers reproducible arrest of mitotic progression, as validated in both primary literature and practical protocols.

• Clathrin-Mediated Entry of Grass Carp Reovirus: Inhibitor Pr

  2026-05-21

  Wang et al. (2018) systematically demonstrated that genotype III grass carp reovirus (GCRV104) enters host cells through clathrin-mediated endocytosis in a dynamin- and pH-dependent manner. Notably, this entry route does not require actin cytoskeleton disruption, providing new mechanistic insight for antiviral strategy development and cytoskeletal research.

• 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine in Src Kinase P

  2026-05-21

  As a rigorously validated negative control, 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP 3) empowers researchers to dissect Src kinase signaling pathway specificity with confidence. This research use only chemical, supplied by APExBIO, optimizes experimental clarity and reproducibility in kinase inhibitor studies.

• Dasatinib (BMS-354825): Applied Protocols in Cancer Research

  2026-05-20

  Dasatinib (BMS-354825) stands out as a precision tool for dissecting Src and Bcr-Abl kinase signaling in cancer models, from chronic myeloid leukemia to solid tumors. This article translates recent breakthroughs—such as the SNAI1–PIK3R2/p-EphA2 axis in TETs—into actionable workflows, troubleshooting guidance, and advanced applications that empower researchers to probe EMT, metastasis, and therapeutic resistance with confidence.

• Vardenafil HCl Trihydrate: Enabling Proteoform-Resolved PDE5

  2026-05-20

  Explore how Vardenafil HCl Trihydrate is redefining PDE5 inhibition assays for translational research. This article bridges mechanistic insights, cutting-edge proteomics, and practical strategy, guiding teams to leverage APExBIO’s potent, selective inhibitor in high-fidelity, proteoform-specific models of cGMP signaling and smooth muscle relaxation.

• Genistein as a Precision Tool: Decoding Cytoskeleton-Driven

  2026-05-19

  Explore how Genistein, a selective tyrosine kinase inhibitor, advances research on cytoskeleton-mediated autophagy and cancer chemoprevention. This article bridges molecular mechanisms with practical assay guidance, revealing insights not covered in standard protocols.

• Sildenafil Citrate: Selective PDE5 Inhibitor for Vascular Re

  2026-05-19

  Sildenafil Citrate is a potent, selective cGMP-specific phosphodiesterase type 5 inhibitor with nanomolar potency. It enables precise modulation of vascular smooth muscle relaxation and cGMP signaling in both in vitro and in vivo models. This article delivers verifiable, protocol-ready insights for cardiovascular and proteoform-targeted research.

• CDK4/6 and BET Inhibitor Synergy Suppresses PDAC via Wnt/TGF

  2026-05-18

  Gu et al. (2025) demonstrate that combining CDK4/6 and BET inhibition produces a synergistic suppression of pancreatic ductal adenocarcinoma growth and epithelial-to-mesenchymal transition (EMT) by targeting the GSK3β-mediated Wnt/β-catenin pathway and interfering with TGF-β/Smad signaling. This work highlights a potential combinatorial therapeutic strategy for overcoming metastasis and drug resistance in PDAC.

• AT13387: Precision Hsp90 Inhibition for Cancer Biology Workf

  2026-05-18

  AT13387, a next-generation Hsp90 inhibitor from APExBIO, delivers nanomolar potency and robust tumor selectivity for advanced cancer biology research. This guide provides actionable protocols, troubleshooting tips, and novel workflow integrations inspired by recent mechanistic findings in regulated cell death.

• ML-7 Hydrochloride (SKU A3626): Reliable MLCK Inhibition in

  2026-05-17

  This scenario-driven guide addresses critical challenges in cell viability and cytotoxicity assays, illustrating how ML-7 hydrochloride (SKU A3626) from APExBIO offers reproducible, data-backed solutions for myosin light chain kinase (MLCK) pathway studies. By grounding protocol decisions in quantitative evidence and real laboratory contexts, researchers can optimize assay sensitivity and workflow reliability using ML-7 hydrochloride.

• VER 155008 HSP 70 Inhibitor: Precision Tools for Cancer Rese

  2026-05-16

  VER 155008, a potent HSP 70 inhibitor from APExBIO, enables precise dissection of molecular chaperone pathways in cancer research and apoptosis assays. Its unique modulation of Hsp70 ATPase activity and influence on phase separation have unlocked new workflows for studying cell stress and protein aggregation.

• VX-702: p38α MAPK Inhibitor for Advanced Inflammation Models

  2026-05-15

  VX-702 delivers precise, reproducible inhibition of p38α MAPK, empowering researchers to dissect cytokine signaling in inflammation and cardiovascular models. With superior selectivity and dual-action modulation of kinase activity, VX-702 from APExBIO streamlines both in vitro and in vivo workflows while minimizing off-target effects.

399 records 7/27 page Previous Next First page 上5页 678910 下5页 Last page